Hospitalisation risks in the treatment of schizophrenia in a Medicaid population: Comparison of antipsychotic medications

International Journal of Clinical Practice

Volumn 60, Issue 11, 2006, Pages 1419-1424

  Gianfrancesco, Frank ^a   Wang, R H ^a   Pesa, J ^b   Rajagopalan, K ^c  

^a HECON Associates Inc   (United States)

^b Ortho McNiel Scientific Affairs   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Antipsychotics; Hospitalisation; Medicaid; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; ZIPRASIDONE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; HEALTH INSURANCE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; UNITED STATES;

ADULT; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; FEMALE; HOSPITALIZATION; HUMANS; MALE; MEDICAID; MIDDLE AGED; OHIO; RECURRENCE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA;

EID: 33749827163     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01161.x     Document Type: Article

References (27)

1. Rice DP. The economic impact of schizophrenia. J Clin Psychiatry 1999; 60 (Suppl. 1): 4-6.
2. Wu EQ, Birbaum HG, Shi L et.al. The economic burden of schizophrenia in the United States. J Clin Psychiatry 2005; 66: 1122-9.
3. Ayuso-Gutierrez JL, del Rio Vega JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 1997; 28: 199-206.
4. Gilmer TP, Dolder CR, Lacro JP et.al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid patients with schizophrenia. Am J Psychiatry 2004; 161: 692-9.
5. Weiden PJ, Kozma C, Grogg A, Locllear J. Partial compliance and risk of rehospitalization among patients with schizophrenia. Psych Serv 2004; 55: 886-91.
6. Csernansky JG, Schuchart EK. Relapse and rehospitalization rates in patients with schizophrenia: Effects of second generation antipsychotics. CNS Drugs 2002; 16: 473-82.
7. Marder SR. Facilitating compliance with antipsychotic medication. J Clin Psychiatry 1998; 59 (Suppl.): 21-5.
8. Mojtabai R, Lavelle J, Gibson PJ, Bromet EJ. Atypical antipsychotics in first admission schizophrenia: Medication continuation and outcomes. Schizophr Bull 2003; 29: 519-30.
9. Brown ES, Thomas NR, Carmody T, Mahadi S, Nejtek VA. Atypical antipsychotics in bipolar and schizoaffective disorders. Pharmacopsychiatry 2001; 34: 80-1.
10. Buckley PF. Novel antipsychotics and patient care in state hospitals. Ann Psychopharmacother 1998; 32: 906-14.
11. Coley KC, Carter CS, DaPos SV, Maxwell R, Wilson JW, Branch RA. Effectiveness of antipsychotic therapy in a naturalistic setting. Comparison between risperidone, perphenazine and haloperidol. J Clin Psychiatry 1999; 60: 850-6.
12. Conley RR, Love RC, Kelly DL, Bartko JJ. Rehospitalization rates of patients recently discharged on regimens of risperidone or clozapine. Am J Psychiatry 1999; 156: 863-8.
13. Conley RR, Kelly DL, Love RC, McMahon RP. Rehospitalization risk with second-generation and depot antipsychotics. Ann Clin Psychiatry 2003; 15: 23-31.
14. Meltzer HY, Cola PA. The pharmacoeconomics of clozapine: A review. J Clin Psychiatry 1994; 55 (Suppl.): 161-5.
15. Patel NC, Dorson PG, Edwards N et.al. One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics. Psych Serv 2002; 53: 891-3.
16. Rabinowitz J, Lichtenberg P, Kaplan Z et.al. Rehospitalization rates of chronically ill schizophrenia patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001; 158: 266-9.
17. Klinkenberg WD, Calsyn RJ. Predictors of psychiatric hospitalization: A multivariate analysis. Adm Policy Ment Health 1998; 25: 403-10.
18. Gianfrancesco F, Wang R, Mahmoud R et.al. Methods for claims-based pharmacoeconomic studies in psychosis. Pharmacoeconomics 2002; 20: 499-511.
19. Olfson M, Mechanic D, Boyer CA, Hansell S, Wallkup J, Weiden PJ. Assessing clinical predictions of early rehospitalization in schizophrenia. J Nerv Ment Dis 1999; 187: 721-9.
20. Gerding LB, Labbate LA, Measom MO, Santos AB, Arana GW. Alcohol dependence and hospitalization in schizophrenia. Schizophr Res 1999; 38: 71-5.
21. Lyons JS, O'Mahoney MT, Miller SI, Neme J, Kabat J, Miller F. Predicting readmission to the psychiatric hospital in a managed care environment: implications for quality indicators. Am J Psych 1997; 154: 337-40.
22. Marken PA, Stanislav SW, Lacombe S et.al. Profile of a sample of subjects admitted to an acute care psychiatric facility with manic symptoms. Psychopharmacol Bull 1992; 28: 201-5.
23. Montgomery P, Kirkpatrick H. Understanding those who seek frequent psychiatric hospitalizations. Arch Psychiatr Nurs 2002; 16: 16-24.
24. Tilden D, Aristides M, Meddis D, Burns T. An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics. Clin Ther 2002; 24: 1648-67.
25. Leiberman JA, Stroup TS, McEvoy JP et.al. Effectiveness of antipsychotic drugs in patients with schizophrenia. N Eng J Med 2005; 353: 1209-23.
26. Gianfrancesco F, Wang R, Pesa J. Relationship between initial quetiapine dose and effectiveness as reflected in subsequent mental health service use among patients with schizophrenia or bipolar disorder. Value Health 2005; 8: 471-8.
27. Salkever DS, Slade EP, Karakus M, Palmer L, Russo P. Estimate of antipsychotic effects of hospitalization risk in a naturalistic study with selection on unobservables. J Nerv Ment Dis 2004; 197: 119-28.